GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more
GenSight Biologics S.A (GSGTF) - Total Liabilities
Latest total liabilities as of June 2025: $39.46 Million USD
Based on the latest financial reports, GenSight Biologics S.A (GSGTF) has total liabilities worth $39.46 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GenSight Biologics S.A - Total Liabilities Trend (2012–2024)
This chart illustrates how GenSight Biologics S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GenSight Biologics S.A Competitors by Total Liabilities
The table below lists competitors of GenSight Biologics S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Finebesteel
KO:133820
|
Korea | ₩132.46 Billion |
|
Fiducial Real Estate SA
PA:ORIA
|
France | €277.05 Million |
|
Damsan JSC
VN:ADS
|
Vietnam | ₫1.49 Trillion |
|
Genesis Scale Holdings Limited
F:92N0
|
Germany | €454.60 Million |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
Brazil | R$24.81 Billion |
|
Aspire Mining Ltd
AU:AKM
|
Australia | AU$955.33K |
|
Manolete Partners Plc
PINK:MANOF
|
USA | $30.89 Million |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
USA | $1.69 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down GenSight Biologics S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenSight Biologics S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenSight Biologics S.A (2012–2024)
The table below shows the annual total liabilities of GenSight Biologics S.A from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.68 Million | -5.42% |
| 2023-12-31 | $39.83 Million | -3.36% |
| 2022-12-31 | $41.22 Million | +1.38% |
| 2021-12-31 | $40.66 Million | +13.91% |
| 2020-12-31 | $35.69 Million | +72.13% |
| 2019-12-31 | $20.74 Million | +58.19% |
| 2018-12-31 | $13.11 Million | +81.67% |
| 2017-12-31 | $7.22 Million | +22.51% |
| 2016-12-31 | $5.89 Million | -15.66% |
| 2015-12-31 | $6.98 Million | +64.81% |
| 2014-12-31 | $4.24 Million | +122.31% |
| 2013-12-31 | $1.91 Million | +1399.90% |
| 2012-12-31 | $127.08K | -- |